BioAge Labs (NASDAQ:BIOA) Upgraded by Wall Street Zen to Hold Rating

BioAge Labs (NASDAQ:BIOA - Get Free Report) was upgraded by Wall Street Zen from a "sell" rating to a "hold" rating in a research report issued on Saturday.

Several other research firms have also issued reports on BIOA. Needham & Company LLC assumed coverage on BioAge Labs in a research note on Friday, March 27th. They set a "buy" rating and a $50.00 price objective for the company. Piper Sandler assumed coverage on BioAge Labs in a research note on Tuesday, January 27th. They set an "overweight" rating for the company. Citigroup increased their price objective on BioAge Labs from $15.00 to $52.00 and gave the stock a "buy" rating in a research note on Tuesday, March 10th. Oppenheimer started coverage on BioAge Labs in a report on Wednesday, February 25th. They set an "outperform" rating and a $60.00 price target for the company. Finally, Weiss Ratings reaffirmed a "sell (d-)" rating on shares of BioAge Labs in a report on Friday, April 24th. Four analysts have rated the stock with a Buy rating and one has assigned a Sell rating to the company. Based on data from MarketBeat, the stock presently has a consensus rating of "Moderate Buy" and a consensus target price of $46.25.

BioAge Labs Price Performance

BioAge Labs stock opened at $17.99 on Friday. The stock has a fifty day moving average price of $18.55 and a two-hundred day moving average price of $15.38. BioAge Labs has a 52-week low of $3.67 and a 52-week high of $24.00. The firm has a market capitalization of $798.40 million, a P/E ratio of -8.03 and a beta of 0.99.

BioAge Labs (NASDAQ:BIOA - Get Free Report) last released its quarterly earnings data on Friday, May 8th. The company reported ($0.52) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.71) by $0.19. BioAge Labs had a negative return on equity of 27.86% and a negative net margin of 896.11%.The firm had revenue of $2.77 million during the quarter. On average, equities research analysts predict that BioAge Labs will post -2.7 EPS for the current fiscal year.

Hedge Funds Weigh In On BioAge Labs

Several institutional investors have recently modified their holdings of BIOA. Russell Investments Group Ltd. acquired a new position in shares of BioAge Labs during the 3rd quarter worth about $27,000. CWM LLC grew its holdings in BioAge Labs by 39.9% during the fourth quarter. CWM LLC now owns 3,693 shares of the company's stock valued at $49,000 after purchasing an additional 1,053 shares during the period. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. grew its holdings in BioAge Labs by 85.6% during the second quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. now owns 12,955 shares of the company's stock valued at $54,000 after purchasing an additional 5,976 shares during the period. Walleye Capital LLC acquired a new position in BioAge Labs during the second quarter valued at approximately $64,000. Finally, Bank of America Corp DE grew its holdings in BioAge Labs by 46.3% during the third quarter. Bank of America Corp DE now owns 11,119 shares of the company's stock valued at $65,000 after purchasing an additional 3,517 shares during the period.

BioAge Labs Company Profile

BioAge Labs NASDAQ: BIOA is a clinical-stage biotechnology company focused on discovering and developing therapies that address age-associated diseases. The company leverages its proprietary analytics platform to mine large-scale human biological data for insights into the molecular mechanisms of aging. By targeting fundamental aging pathways, BioAge aims to create interventions that extend healthspan and treat conditions that disproportionately affect older populations.

At the core of BioAge’s operations is its integrated drug discovery platform, which combines human omics datasets, machine learning algorithms and experimental validation to identify novel drug targets.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.